Silverarc Capital Management, LLC holds a diversified book of 65 stocks worth $898.5M as of Q2 2026 (disclosed Aug 13, 2026, a ~44-day 13F lag). This quarter they opened Ascendis Pharma A/s and trimmed Cogent Biosciences Inc. Their largest long position is Ascendis Pharma A/s at 6% of the equity book. They also disclosed $25.7M in put options (a bearish bet) and $37.9M in call options (bullish), shown separately below and excluded from the equity book. Cloning the disclosed picks since 2024 would be +106% (+51.3%/yr). That is a simulation of the disclosed long book, not audited returns.
Following at the filing date actually beat the quarter-end book by 24.5 points over this window.
Growth of $10,000 cloning Silverarc Capital Management, LLC's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~44 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
98% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Silverarc Capital Management, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 72 / 65 | $6.4B |
| UBS Group AG | 72 / 65 | $2.2B |
| MORGAN STANLEY | 70 / 65 | $2.5B |
| STATE STREET CORP | 68 / 65 | $9.7B |
| JPMORGAN CHASE & CO | 68 / 65 | $5.2B |
| BlackRock, Inc. | 67 / 65 | $17.5B |
| GOLDMAN SACHS GROUP INC | 66 / 65 | $3.0B |
| NORTHERN TRUST CORP | 66 / 65 | $1.6B |
Ranked by how many of Silverarc Capital Management, LLC's top 65 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Ascendis Pharma A/s ORD SHS | $55.0M | 206.2K | 6.1% | ▲New New position | |
| 2 | Celcuity Inc COM | $52.4M | 501.0K | 5.8% | ▲+40% Added · +143K sh | |
| 3 | Cogent Biosciences Inc COM | $49.6M | 1.28M | 5.5% | ▼−2.5% Reduced · −33K sh | |
| 4 | Urogen Pharma Ltd COM | $47.9M | 1.30M | 5.3% | ▼−13% Reduced · −201K sh | |
| 5 | Immunome Inc COM | $42.7M | 2.02M | 4.8% | ▲+9.0% Added · +167K sh | |
| 6 | Dianthus Therapeutics Inc COM | $38.0M | 390.0K | 4.2% | ▼−40% Reduced · −265K sh | |
| 7 | Rhythm Pharmaceuticals Inc COM | $34.6M | 311.5K | 3.8% | ▲+1.8% Added · +5K sh | |
| 8 | Oruka Therapeutics Inc COM | $33.6M | 352.8K | 3.7% | ▲+134% Added · +202K sh | |
| 9 | Monte Rosa Therapeutics Inc COM | $26.8M | 1.11M | 3.0% | ▼−45% Reduced · −894K sh | |
| 10 | Syndax Pharmaceuticals Inc COM | $26.5M | 1.21M | 3.0% | ▲+37% Added · +325K sh | |
| 11 | Enliven Therapeutics Inc COM | $24.8M | 489.4K | 2.8% | ▲New New position | |
| 12 | Immunovant Inc COM | $23.9M | 619.1K | 2.7% | ▲+49% Added · +205K sh | |
| 13 | Erasca Inc COM | $23.1M | 1.26M | 2.6% | ▼−32% Reduced · −589K sh | |
| 14 | Sagimet Biosciences Inc COM SER A | $22.6M | 2.93M | 2.5% | ▲New New position | |
| 15 | Abivax Sa SPONSORED ADS | $22.6M | 169.6K | 2.5% | ▼−44% Reduced · −133K sh | |
| 16 | Praxis Precision Medicines I COM NEW | $22.0M | 65.7K | 2.4% | ▼−8.2% Reduced · −6K sh | |
| 17 | Kodiak Sciences Inc COM | $21.3M | 546.3K | 2.4% | ▼−45% Reduced · −446K sh | |
| 18 | Definium Therapeutics Inc COM SHS | $18.8M | 400.0K | 2.1% | ▲New New position | |
| 19 | Veracyte Inc COM | $18.7M | 318.0K | 2.1% | ▲+77% Added · +138K sh | |
| 20 | Guardant Health Inc COM | $15.0M | 99.8K | 1.7% | ▲+1.3% Added · +1K sh | |
| 21 | C4 Therapeutics Inc COM STK | $14.2M | 3.03M | 1.6% | ▲+59% Added · +1.1M sh | |
| 22 | Zenas Biopharma Inc COM | $12.9M | 509.8K | 1.4% | ▼−55% Reduced · −626K sh | |
| 23 | Trevi Therapeutics Inc COM | $12.6M | 678.1K | 1.4% | ▲+33% Added · +167K sh | |
| 24 | Helix Acquisition Corp III USD CL A ORD SHS | $12.5M | 1.18M | 1.4% | ▼−2.6% Reduced · −31K sh | |
| 25 | Alx Oncology Hldgs Inc COM | $11.9M | 5.74M | 1.3% | ▲New New position | |
| 26 | Veradermics Inc COMMON STOCK | $11.7M | 95.0K | 1.3% | ▲New New position | |
| 27 | Xenon Pharmaceuticals Inc COM | $11.3M | 186.8K | 1.3% | ▼−5.5% Reduced · −11K sh | |
| 28 | Avalyn Pharmaceuticals Inc COM SHS | $10.9M | 330.5K | 1.2% | ▲New New position | |
| 29 | Biogen Inc COM | $10.4M | 48.1K | 1.2% | ▼−5.6% Reduced · −3K sh | |
| 30 | Aclaris Therapeutics Inc COM | $10.3M | 1.95M | 1.1% | ▲New New position | |
| 31 | Cerus Corp COM | $10.1M | 3.47M | 1.1% | ▲+9.3% Added · +296K sh | |
| 32 | Avalo Therapeutics Inc COM NEW | $9.2M | 500.4K | 1.0% | ▲New New position | |
| 33 | Benitec Biopharma Inc COM NEW | $9.1M | 679.8K | 1.0% | ▼−5.3% Reduced · −38K sh | |
| 34 | Vaxcyte Inc COM | $8.4M | 145.0K | 0.9% | ▲~0% Added · +19 sh | |
| 35 | Genedx Holdings Corp COM CL A | $8.4M | 122.3K | 0.9% | ▲New New position | |
| 36 | Savara Inc COM | $8.3M | 1.36M | 0.9% | ▼−5.3% Reduced · −76K sh | |
| 37 | Ovid Therapeutics Inc COM | $8.3M | 3.10M | 0.9% | ▲+210% Added · +2.1M sh | |
| 38 | Oric Pharmaceuticals Inc COM | $8.0M | 738.9K | 0.9% | ▼−33% Reduced · −361K sh | |
| 39 | Compass Pathways PLC SPONSORED ADS | $7.1M | 503.4K | 0.8% | ▲+68% Added · +203K sh | |
| 40 | Compugen Ltd ORD | $6.8M | 3.18M | 0.8% | ▼−4.0% Reduced · −132K sh | |
| 41 | Solid Biosciences Inc COM NEW | $6.7M | 668.5K | 0.7% | ▲New New position | |
| 42 | Ibio Inc COM NEW | $6.2M | 3.52M | 0.7% | ▲16× Added · +3.3M sh | |
| 43 | Disc Medicine Inc COM | $6.1M | 82.8K | 0.7% | ▼−58% Reduced · −113K sh | |
| 44 | Alkermes PLC SHS | $5.9M | 113.5K | 0.7% | ▼−75% Reduced · −347K sh | |
| 45 | Spyre Therapeutics Inc COM NEW | $5.3M | 60.0K | 0.6% | ▼−68% Reduced · −127K sh | |
| 46 | Artiva Biotherapeutics Inc COM | $5.1M | 525.0K | 0.6% | ▲New New position | |
| 47 | Contineum Therapeutics Inc CL A | $4.9M | 296.1K | 0.5% | ▼−1.9% Reduced · −6K sh | |
| 48 | Uniqure NV SHS | $4.8M | 105.0K | 0.5% | ▲New New position | |
| 49 | Research Alliance Corp III ORD SHS CL A | $3.9M | 360.0K | 0.4% | ▲New New position | |
| 50 | Abeona Therapeutics Inc COM NEW | $3.8M | 610.4K | 0.4% | ▼−5.9% Reduced · −39K sh |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1816307/holdings"
Use Arkolith to show SILVERARC CAPITAL MANAGEMENT, LLC's latest holdings, largest changes, and filing provenance.
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | ARK ETF TR | $21.0M | 500K |
| CALL · bullish | SYNDAX PHARMACEUTICALS INC | $15.2M | 694K |
| CALL · bullish | ORIC PHARMACEUTICALS INC | $7.4M | 683K |
| CALL · bullish | MONTE ROSA THERAPEUTICS INC | $7.3M | 300K |
| CALL · bullish | ABIVAX SA | $6.7M | 50K |
| PUT · bearish | KYMERA THERAPEUTICS INC | $2.9M | 25K |
| PUT · bearish | ABSCI CORPORATION | $1.8M | 158K |
| CALL · bullish | FULCRUM THERAPEUTICS INC | $1.4M | 392K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Aug 13, 2026 | 73 | $962.2M | 13F-HR |
| Q1 2026 | Mar 31, 2026 | May 14, 2026 | 73 | $979.8M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 12, 2026 | 68 | $720.1M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 12, 2025 | 82 | $741.6M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 65 | $542.3M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 14, 2025 | 69 | $489.0M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 61 | $457.2M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 71 | $445.3M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.